Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26491481 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL20876854 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL1457445 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL8372916 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| Tetrahydropellitorine SCHEMBL4878046 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL443535 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL7432688 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL1456461 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL9462479 | 0.98 | FAAH (0.61) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| Hydrochloric Acid SCHEMBL5396087 | 0.96 | FAAH (0.59) | FAAHMEN1MAPK1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290950-A1 | ALKAMIDE COMPOUNDS AND USES THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| WO-2019071093-A1 | ALKAMIDE COMPOUNDS AND USES THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290950-A1 | ALKAMIDE COMPOUNDS AND USES THEREOF | ALK, ENPP2, CYSLTR2 | FAAH 25/4885MEN1 4130/4885MAPK1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.